Metabolic Regulation in the Development of Cardiovascular Disease and Heart Failure 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 3641
Special Issue Editor
Interests: cardiology; heart failure; cardiac arrest
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the continuation of our previous Special Issue, entitled "Metabolic Regulation in the Development of Cardiovascular Disease and Heart Failure".
Metabolic regulation is strongly related to the development of cardiovascular diseases and heart failure. Different metabolic diseases can predispose the patient to the occurrence of systolic and diastolic dysfunction and, consequently, to heart failure. Among those, impaired glucose metabolism is the metabolic condition most commonly associated with a greater incidence of both coronary artery disease and heart failure. Novel classes of hypoglycemic drugs, such as type 2 sodium-glucose cotransporter inhibitors (SGLT2i) or GLP-1 agonists, have been demonstrated to exert greater cardio- and nefro-protection effects. In particular, the use of SGLT2i reduce the risk of heart failure occurrence and of heart failure progression.
However, metabolic regulation in cardiovascular disease and heart failure is complex, and its different stages are characterized by differences in metabolic and hormonal status. In patients with advanced heart failure, the dysregulation of metabolism is associated with a greater catabolic status due to a number of pathophysiological mechanisms. These are responsible for paradoxical epidemiology and cardiac cachexia. The study of the metabolic therapeutic approaches used to treat heart failure patients at different stages is a challenging field of research. This Special Issue aims to present a collection of reviews and original papers that better clarify a range of topics, from the pathophysiological, diagnostic, and therapeutic aspects of metabolic regulation related to the risk of cardiovascular disease occurrence through to the onset and progression of heart failure.
Dr. Massimo Iacoviello
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes
- metabolism
- dyslipidemia
- cardiovascular disease
- heart failure
- diagnosis
- prognosis
- therapy
